Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001797537-21-000002)

Filing Details

Accession Number:
0001797537-21-000002
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-17 17:23:17
Reporting Period:
2021-06-15
Accepted Time:
2021-06-17 17:23:17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1372299 Ocugen Inc. OCGN Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1797537 Manish Potti C/O Ocugen, Inc.
263 Great Valley Parkway
Malvern PA 19355		 Yes No No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-06-15 95,880 $6.30 159,309 No 4 X Indirect Held by Scotland Parkway LLC
Common Stock Disposition 2021-06-15 68,185 $8.86 91,124 No 4 S Indirect Held by Scotland Parkway LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 X Indirect Held by Scotland Parkway LLC
No 4 S Indirect Held by Scotland Parkway LLC
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrant (Right to Buy) Disposition 2021-06-15 95,880 $0.00 95,880 $6.30
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-09-27 2026-12-15 No 4 X Indirect
Footnotes
  1. The Reporting Person is a managing member of Scotland Parkway LLC and has voting and investment power over securities held by Scotland Parkway LLC.
  2. On June 15, 2021, the Reporting Person exercised a warrant to purchase 95,880 shares of common stock for $6.30 a share. The Reporting Person paid the exercise price on a cashless basis, resulting in the Company's withholding of 68,185 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 27,695 shares. The Company also paid $4.89 to the Reporting Person in lieu of a fractional share.